Replicor Inc. Logo
2016-02-16 22:00
Replicor to Present Pre-Clinical and Updated Clinical Data on REP 2139-Ca Based Combination Therapy in Chronic HBV and HBV / HDV Co-Infection at APASL 2016
NEW YORK--(Business Wire/Korea Newswire) February 16, 2016 -- Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, will present preclinical and updated clinical data on REP 2139-Ca based combination therapies in HBV infection and HBV / HDV co-infection at the 25th Annual Meeting of the Asia Pacific Association for the Study of the Liver to be held from February 20 -24, 2016 in Toyko, Japan. Three presentations on Replicor technology will be made during the meeting:

HBV RNA is emerging as a potential new marker of viremia in patients with HBV infection. In patients with HBeAg positive HBV infection, treatment with REP 2139-Ca and immunotherapy (in the REP 102 protcol), not only leads to reduction / clearance of HBsAg and HBV DNA and the appearance of anti-HBs but also to reduction of HBV RNA as well. The characterization of the HBV RNA response in the REP 102 protocol was done in collaboration with the lab of Dr. Hendrik Reesink at the Amsterdam Medical Center, and will be presented by Dr. Reesink in the Presidential Plenary Session on February 22nd.

An update on the clinical response data from HBV /HDV co-infected patients completing REP 2139-Ca / peg-interferon combination therapy and transitioning to peg-interferon monotherapy in the REP 301 protocol will be presented in an oral presentation on Feb 22nd (O-130).

A poster presentation on the effects of combined treatment with REP 2139-Ca and tenofovir disoproxil fumarate and entecavir on serum and liver virema in vivo will be presented on Feb 22nd (P-0329).

These pre-clinical and clinical studies continue to advance Replicor’s understanding of the antiviral effects of REP 2139-Ca based combination therapies and how these can be used to benefit patients with HBV infection or HBV / HDV co-infection.

For the APASL 2016 meeting and preliminary program:

About Replicor

Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV infection. For further information about Replicor please visit our website at

View source version on
Replicor Inc. 전체 보도자료 보기
이 뉴스는 기업·기관이 발표한 보도자료 전문입니다. 언론 매체와 블로그는 보도를 목적으로 이 보도자료를 사용할 수 있습니다. 보도자료 등록 안내
Media Contact

For Replicor Inc.
Alexandra Peterson

이 보도자료 관련 분야

건강  제약  사업계획  해외

관심 분야 보도자료 구독 방법

가입하면 관심 분야 보도자료를 마이 뉴스와 이메일로 볼 수 있습니다. 스마트폰과 RSS로도 가능합니다.

보도자료 배포 서비스 안내

뉴스와이어는 4천여개 언론매체에서 일하는 1만7천여명의 기자에 보도자료를 배포해 언론이 보도할 수 있게 합니다.

해외 보도자료 배포 안내
비즈니스와이어와 제휴해 해외 언론에 보도자료를 배포합니다.